Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 11/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.40 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.40 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.40 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.40 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123816 | 1.00 | TTK (0.47) | TTKPTK2AXLGUCY1B2GUCY1A2 | |
| SCHEMBL24940103 | 0.96 | TTK (0.48) | TTKPTK2AXLPTK6 | |
| SCHEMBL24940135 | 0.96 | TTK (0.48) | TTKPTK2AXLPTK6 | |
| SCHEMBL22124088 | 0.93 | TTK (0.47) | TTKPTK2AXLPTK6 | |
| SCHEMBL22124142 | 0.92 | TTK (0.41) | TTKPTK2AXLGUCY1B2GUCY1A2 | |
| SCHEMBL30187385 | 0.92 | TTK (0.41) | TTKPTK2AXLGUCY1B2GUCY1A2 | |
| SCHEMBL22123809 | 0.92 | TTK (0.51) | TTKPTK2AXLPTK6 | |
| SCHEMBL30187312 | 0.92 | TTK (0.51) | TTKPTK2AXLPTK6 | |
| SCHEMBL24940120 | 0.88 | TTK (0.44) | TTKPTK2AXLPTK6 | |
| SCHEMBL24112462 | 0.88 | TTK (0.50) | TTKPTK2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898629-B1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | claimed |
| EP-4161931-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | TTK 4519/4885PTK2 4505/4885AXL 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.